Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda

International Journal of STD and AIDS

Volumn 21, Issue 8, 2010, Pages 553-557

  Ocama, P ^a   Castelnuovo, B ^a   Kamya, M R ^a   Kirk, G D ^b   Reynolds, S J ^b,c   Kiragga, A ^a   Colebunders, R ^d   Thomas, D L ^b  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral therapy; AST; Liver toxicity; Nevirapine

Indexed keywords

ABACAVIR; ALLUVIA; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; UGANDA; URBAN POPULATION; VIRUS DETECTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; LIVER; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UGANDA;

EID: 78049450483     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010027     Document Type: Article

References (27)

1. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 2000;19:2526-7
2. Lana R, Nunez M, Mendoza JL, Soriano V. Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. Med Clin (Barc) 2001;117:607-10 (Pubitemid 33123297)
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41
4. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197(Suppl. 3):S279-93
5. Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007;334:334-41
6. Sanne I, Mommeja-Martin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-9
7. Mbougua JB, Laurent C, Kouanfack C, et al. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 2010;10:105-15
8. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus and risk of liver related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6
9. Kamya M, Mayanja-Kizza H, Kambugu A. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-93
10. Weidle PJ, Moore D, Mermin J, et al. Liver enzymes improve over twenty-four months of first line non-nucleoside reverse trancriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS 2008;10:787-95
11. Mugyenyi P, Walker S, Hakim J, et al. Routine versus clinicaly driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 2010;375:123-31
12. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-31
13. Burnett RJ, Francois G, Kew MC, et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 2005;25:201-13 (Pubitemid 40500550)
14. Ocama P, Katwere M, Piloya T, et al. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci 2008;8:8-12
15. Iwalokun BA, Hodonu SO, Olaleye BM, Olabisi OA. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria. Afr J Med Sci 2006;35:337-43
16. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21:1301-8
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol 2009;50:227-43
18. Thio C, Locarnini S. Treatment of HIV-HBV co-infection: clinical and virological issues. AIDS Rev 2007;9:40-53
19. Bellini C, Keiser O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009;10:12-18
20. Bhattacharya D, Katzenstein D, Wong A, et al. Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. Int J STD AIDS 2008;19:780-1
21. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133:1452-7
22. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008;47:1468-75
23. Seremba E, Ocama P, Opio KC, et al. validity of Rapid Strip Assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol 2010;82:1334-40
24. Castelnuovo B, Yuka M, Kiragga A, Moses K, Philippa E, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first three years after antiretroviral therapy in an urban African cohort. Clin Infect Dis 2009;49:965-72
25. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005;41:123-31
26. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;16:2209-16
27. Sellier P, Schnepf N, Jarrin I, et al. Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol 2010;47:13-17